Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 18/20 | 0.50 |
| ▸ | ITGAV | P06756 | 18/20 | 0.50 |
| ▸ | ITGB6 | P18564 | 5/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 7/20 | 0.47 |
| ▸ | ITGB5 | P18084 | 7/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6223237 | 0.99 | ITGB3 (0.49) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL6224327 | 0.92 | ADRA2A (0.55) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL7752171 | 0.92 | ITGB3 (0.50) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| Formic Acid SCHEMBL15456443 | 0.87 | ADRA2A (0.50) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL19265544 | 0.84 | ITGB3 (0.63) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL30073956 | 0.81 | ITGB3 (0.63) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL6225428 | 0.81 | ITGB3 (0.63) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL19090485 | 0.81 | KDM4E (0.48) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6228601 | 0.76 | ITGB3 (0.55) | ITGB3ITGAVITGB6ITGA2BITGB1 | |
| SCHEMBL6222030 | 0.76 | ITGB3 (0.55) | ITGB3ITGAVITGB6ITGB1ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2875021-B1 | BETA AMINO ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | UNIV SAINT LOUIS (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-1572210-A1 | THE R-ISOMER OF BETA AMINO ACID COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050020505-A1 | R-isomer of beta amino acid compounds as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-01-27 | — | — | US | disclosed |
| WO-2004060376-A1 | THE R-ISOMER OF BETA AMINO ACID COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | PHARMACIA CORPRATION (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060376-A1 | THE R-ISOMER OF BETA AMINO ACID COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | PHARMACIA CORPRATION (US) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020505-A1 | R-isomer of beta amino acid compounds as integrin receptor antagonists derivatives | ITGA5, ITGAL, ITGB5 | ITGB3 9/4885ITGAV 4/4885ITGB6 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.